PuSH - Publication Server of Helmholtz Zentrum München

Journal browsing

64 Records found.
Zum Exportieren der Ergebnisse bitte einloggen.
▮◀ ◀◀ 1 ... 2 ... 3 ... 4 ... ▶▶ ▶▮
Lay all publications on this page into basket
1.
Atar, D.* et al.: Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia. Leukemia, DOI: 10.1038/s41375-024-02351-2 (2024)
2.
Sperk, A.* et al.: FBXL6 is a vulnerability in AML and unmasks proteolytic cleavage as a major experimental pitfall in myeloid cells. Leukemia, DOI: 10.1038/s41375-024-02345-0 (2024)
3.
Klann, K.* et al.: Correction: Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia. Leukemia 36:2950 (2022)
4.
Koschade, S.E.* et al.: Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia. Leukemia 36, 2396-2407 (2022)
5.
Massacci, G.* et al.: A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients. Leukemia 37, 288-297 (2022)
6.
Mentz, M. et al.: PARP14 is a novel target in STAT6 mutant follicular lymphoma. Leukemia 36, 2281–2292 (2022)
7.
Wirth, A.-K. et al.: In vivo PDX CRISPR/Cas9 screens reveal mutual therapeutic targets to overcome heterogeneous acquired chemo-resistance. Leukemia 36, 2863–2874 (2022)
8.
Benmebarek, M.R.* et al.: A modular and controllable T cell therapy platform for acute myeloid leukemia. Leukemia 35, 2243–2257 (2021)
9.
Stegelmann, F.* et al.: Publisher Correction: Significant association of cutaneous adverse events with hydroxyurea: Results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN (Leukemia, (2021), 35, 2, (628-631), 10.1038/s41375-020-0945-3). Leukemia, DOI: 10.1038/s41375-021-01366-3 (2021)
10.
Bamezai, S.* et al.: TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition. Leukemia 35, 389–403 (2020)
11.
Bamopoulos, S.A.* et al.: Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia. Leukemia 34, 2621–2634 (2020)
12.
Herold, T. et al.: Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia 34, 3161–3172 (2020)
13.
Jensen, P.* et al.: Requirement for LIM kinases in acute myeloid leukemia. Leukemia 34, 3173–3185 (2020)
14.
Mason, M.J.* et al.: Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease. Leukemia 34, 1866–1874 (2020)
15.
Ruzicka, M.* et al.: RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade. Leukemia 34, 1017-1026 (2020)
16.
Stegelmann, F.* et al.: Significant association of cutaneous adverse events with hydroxyurea: Results from a prospective non-interventional study inBCR-ABL1-negative myeloproliferative neoplasms (MPN)-on behalf of the German Study Group-MPN. Leukemia, DOI: 10.1038/s41375-020-0945-3 (2020)
17.
Stief, S.M.* et al.: Loss of KDM6A confers drug resistance in acute myeloid leukemia. Leukemia 34, 50-62 (2020)
18.
Tirado-Gonzalez, I.* et al.: Correction: CRISPR/Cas9-edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC (Leukemia, (2018), 32, 4, (1048-1051), 10.1038/leu.2017.346). Leukemia 35:294 (2020)
19.
Angenendt, L.* et al.: The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia. Leukemia 33, 2830-2841 (2019)
20.
Lynch, J.R.* et al.: JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis. Leukemia 33, 1400-1410 (2019)
▮◀ ◀◀ 1 ... 2 ... 3 ... 4 ... ▶▶ ▶▮